GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Cyclically Adjusted Revenue per Share

QuidelOrtho (QuidelOrtho) Cyclically Adjusted Revenue per Share : $25.89 (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is QuidelOrtho Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

QuidelOrtho's adjusted revenue per share for the three months ended in Dec. 2023 was $11.117. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $25.89 for the trailing ten years ended in Dec. 2023.

During the past 12 months, QuidelOrtho's average Cyclically Adjusted Revenue Growth Rate was 21.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 34.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 34.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of QuidelOrtho was 42.90% per year. The lowest was -4.00% per year. And the median was 5.60% per year.

As of today (2024-04-28), QuidelOrtho's current stock price is $39.64. QuidelOrtho's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $25.89. QuidelOrtho's Cyclically Adjusted PS Ratio of today is 1.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of QuidelOrtho was 35.44. The lowest was 1.51. And the median was 6.03.


QuidelOrtho Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for QuidelOrtho's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Cyclically Adjusted Revenue per Share Chart

QuidelOrtho Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.31 10.76 14.92 21.35 25.89

QuidelOrtho Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.35 22.74 23.86 25.06 25.89

Competitive Comparison of QuidelOrtho's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, QuidelOrtho's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QuidelOrtho's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, QuidelOrtho's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where QuidelOrtho's Cyclically Adjusted PS Ratio falls into.



QuidelOrtho Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, QuidelOrtho's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=11.117/129.4194*129.4194
=11.117

Current CPI (Dec. 2023) = 129.4194.

QuidelOrtho Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.365 99.695 1.772
201406 0.917 100.560 1.180
201409 1.195 100.428 1.540
201412 1.839 99.070 2.402
201503 1.726 99.621 2.242
201506 1.018 100.684 1.309
201509 1.390 100.392 1.792
201512 1.566 99.792 2.031
201603 1.538 100.470 1.981
201606 1.203 101.688 1.531
201609 1.510 101.861 1.919
201612 1.605 101.863 2.039
201703 2.168 102.862 2.728
201706 1.142 103.349 1.430
201709 1.501 104.136 1.865
201712 3.347 104.011 4.165
201803 4.032 105.290 4.956
201806 2.720 106.317 3.311
201809 2.737 106.507 3.326
201812 3.097 105.998 3.781
201903 3.449 107.251 4.162
201906 2.613 108.070 3.129
201909 2.928 108.329 3.498
201912 3.515 108.420 4.196
202003 4.024 108.902 4.782
202006 4.612 108.767 5.488
202009 10.920 109.815 12.869
202012 18.552 109.897 21.848
202103 8.622 111.754 9.985
202106 4.165 114.631 4.702
202109 11.995 115.734 13.413
202112 14.442 117.630 15.890
202203 23.639 121.301 25.221
202206 11.595 125.017 12.003
202209 11.612 125.227 12.001
202212 12.933 125.222 13.367
202303 12.610 127.348 12.815
202306 9.957 128.729 10.010
202309 11.121 129.860 11.083
202312 11.117 129.419 11.117

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


QuidelOrtho  (NAS:QDEL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

QuidelOrtho's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=39.64/25.89
=1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of QuidelOrtho was 35.44. The lowest was 1.51. And the median was 6.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


QuidelOrtho Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


QuidelOrtho (QuidelOrtho) Business Description

Traded in Other Exchanges
Address
9975 Summers Ridge Road, San Diego, CA, USA, 92121
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Executives
Louise Brandy officer: SVP, Chief Information Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein officer: Chief Administrative Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith director 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael director 618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy officer: SVP, Cardio/Metabolic Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll officer: SVP, Research and Development 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler director
Robert R. Schmidt director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli officer: SVP, Molecular Bus. Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski officer: See Remarks C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr. director 82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges officer: SVP, General Counsel 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant director, officer: Chairman & CEO C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015